Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Idera Pharmaceuticals, Inc.

Home Clinical Trial Sponsors and OrganizationsIdera Pharmaceuticals, Inc.

Idera Pharmaceuticals, Inc.

ACTIVE

马萨诸塞州米德尔塞克斯县, Massachusetts, United Stateswww.aceragen.comPublic51–100 employeesEstablished: 1989-01-01

Part of Aceragen

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

31

18 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

1989

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

18

58.1%

Phase 2

6

19.4%

Phase 3

2

6.5%

Trial Status Distribution

Active, not recruiting

18

58.1%

Completed

11

35.5%

Terminated

2

6.5%

Clinical Trials

Trials sponsored by this organization (31)

A Clinical Trial to compare the effectiveness of the study drug IMO-2125 given in combination with Ipilimumab (a drug indicated for the treatment of advanced melanoma) compared to Ipilimumab given alone in subjects with Refractory Melanoma

Active, not recruiting

Jan 2021454 participants

Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)

Active, not recruiting

Oct 201930 participants

A Clinical Trial to compare the effectiveness of the study drug Tilsotomod (IMO-2125) given in combination with Ipilimumab and Nivolumab in subjects with solid tumors

Active, not recruiting

May 201941 participants

A Clinical Trial to compare the effectiveness of the study drug IMO-2125 given in combination with Ipilimumab (a drug indicated for the treatment of advanced melanoma) compared to Ipilimumab given alone in subjects with Refractory Melanoma

Active, not recruiting

Nov 2018308 participants

A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma

May 2018481 participants

A Clinical Trial to compare the effectiveness of the study drug IMO-2125 given in combination with Ipilimumab (a drug indicated for the treatment of advanced melanoma) compared to Ipilimumab given alone in subjects with Refractory Melanoma

Active, not recruiting

Apr 2018454 participants

A Clinical Trial to compare the effectiveness of the study drug IMO-2125 given in combination with Ipilimumab (a drug indicated for the treatment of advanced melanoma) compared to Ipilimumab given alone in subjects with Refractory Melanoma

Active, not recruiting

Mar 2018308 participants

A Clinical Trial to compare the effectiveness of the study drug IMO-2125 given in combination with Ipilimumab (a drug indicated for the treatment of advanced melanoma) compared to Ipilimumab given alone in subjects with Refractory Melanoma

Active, not recruiting

Mar 2018470 participants

Page 1 of 4

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials31
Approvals
News

Back to Organizations